Lucira Health jumps on distribution deal for COVID-19 test kits
** Shares of medical tech co LHDX.O up 9.4% at $8.81 in
thin premarket trade
** Signs new distribution agreement with health solutions
providers, Co-Defend and Co-Protect, for at least 600,000 of
LHDX's at-home COVID-19 self-test kits in 2022 urn:newsml:reuters.com:*:nGNX7TC67p
** Financial terms of deal undisclosed
** Two of three brokerages rate the stock "hold" while the
third has "sell"; their median PT is $8
** Up to Tuesday's close, stock fell over 50% from its IPO
price of $17; co listed on Feb. 5
(Reporting by Leroy Leo)
((Leroy.Dsouza@thomsonreuters.com;))
Recent news on Lucira Health
See all newsBrief: Lucira Health Inc Filed Its Amended Chapter 11 Plan Of Liquidation With Bankruptcy Court
Brief: Lucira Health Files Proposed Chapter 11 Plan Of Liquidation
Brief: Bankruptcy Court Approves Lucira Health Assets Sale To Pfizer
Brief: Lucira Health Inc Says On April 6, 2023 Co Held Auction Relating To Disposition Of All Or Substantially All Of Company's Assets
Brief: Lucira Health Announces U.S. Launch Of First & Only At-Home Combination Covid-19 & Flu Test Amidst Sale Process